AUG 20, 2015 3:37 PM PDT

Mutations of Immune Cell Cancer

WRITTEN BY: Ilene Schneider
The culprits in a rare immune cell cancer called cutaneous T-cell lymphoma may be a group of mutations in 15 genes for proteins that work together in a T-cell-survival mechanism. When the mutations keep the mechanism from turning off, the T cells keep multiplying. Researchers at the Stanford University School of Medicine have identified the mutations, which may help to determine treatments for a condition that is currently incurable. The findings were published online August 10 in Nature Genetics and reported in Drug Discovery & Development.
Discovering mutations for rare cancer can lead to effective treatment. 
Rashes, skin tumors and leukemia are manifestations of cutaneous T-cell lymphoma, which responds poorly to traditional chemotherapy. A technique called total skin electron radiation that was developed at Stanford has some effect on it. A new stem cell transplant therapy, also developed at Stanford, has potential for long-term remission for people with advanced, high-risk cutaneous T-cell lymphoma.
 
Because the role of the proteins has been identified, new strategies can be developed for fighting the disease. Now researchers can seek drugs to diminish the malfunctioning proteins from the mutations.
 
According to Youn Kim, MD, professor of dermatology and one of the paper’s authors, “We can now design drug trials in a smart, evidence-based way that is specific to the patient.”
 
Before doctors can prescribe drugs targeted to specific proteins, they have to determine which mutations in the cell-survival pathway their patients’ malignant T cells carry. Such mutations were not present in 60 percent of these cancers sequenced by the researchers.
 
As senior author Paul Khavari, MD, PhD, professor and chair of dermatology, explained, “It really highlights that the future of many types of cancer treatment is going to be: first, know the cancer by sequencing it, and then tailor the therapy specifically.”
 
Four of the patients had a mutation that replaced a specific amino acid in the tumor necrosis factor receptor 2, a protein in the cell membrane that gets signals from outside the cell. Because of the mutation, the receptor was locked into an always-on state, keeping the cell-survival pathway from shutting down. Previous studies showed that patients who had increased TNFR2 protein in their bloodstream had more aggressive forms of the cancer that were more likely to recur after treatment. Thus, the researchers looked at the other patients’ DNA to determine whether duplications triggered the elevated levels in the blood and heightened signaling to activate the cell-survival pathway. They determined that 10 of the patients had multiple copies of the TNFR2 gene and then confirmed the biological role of TNFR2 by growing cells in the lab with either the amino acid mutation or the duplicate TNFR2 genes and demonstrating that the cell-survival pathway was more active than normal cells.
About the Author
  • Ilene Schneider is the owner of Schneider the Writer, a firm that provides communications for health care, high technology and service enterprises. Her specialties include public relations, media relations, advertising, journalistic writing, editing, grant writing and corporate creativity consulting services. Prior to starting her own business in 1985, Ilene was editor of the Cleveland edition of TV Guide, associate editor of School Product News (Penton Publishing) and senior public relations representative at Beckman Instruments, Inc. She was profiled in a book, How to Open and Operate a Home-Based Writing Business and listed in Who's Who of American Women, Who's Who in Advertising and Who's Who in Media and Communications. She was the recipient of the Women in Communications, Inc. Clarion Award in advertising. A graduate of the University of Pennsylvania, Ilene and her family have lived in Irvine, California, since 1978.
You May Also Like
JUL 19, 2020
Drug Discovery & Development
Nanodrug for Treating Invasive Breast Cancer
JUL 19, 2020
Nanodrug for Treating Invasive Breast Cancer
Scientists at the University of Arkansas created a nano-drug that may eradicate triple-negative breast cancer cells. Fin ...
JUL 31, 2020
Cancer
Using Electric Fields to Treat Brain Cancer
JUL 31, 2020
Using Electric Fields to Treat Brain Cancer
One of the great things about research is its creativity, which can lead to interesting experiments, odd but impactful i ...
AUG 21, 2020
Cancer
Investigating Cancer's Metabolism for a New Drug Target
AUG 21, 2020
Investigating Cancer's Metabolism for a New Drug Target
Cancer cells are quite similar to normal cells in many ways, but it’s the small differences that really matter. On ...
AUG 16, 2020
Cancer
Cancer mapping shows health disparities in remote areas
AUG 16, 2020
Cancer mapping shows health disparities in remote areas
Scientists mapping cancer statistics have developed a new mathematical model to track health inequalities relating to th ...
SEP 02, 2020
Cancer
Does Adjuvant Chemotherapy Really Help in a Rare Signet-ring Cell Carcinoma
SEP 02, 2020
Does Adjuvant Chemotherapy Really Help in a Rare Signet-ring Cell Carcinoma
For many rare diseases, there is a lack of a “standard” treatment options. This is more prevalent in diverse ...
SEP 14, 2020
Genetics & Genomics
Why Defects in One Gene Can Lead to Cancer in Kids
SEP 14, 2020
Why Defects in One Gene Can Lead to Cancer in Kids
While they may occur in adults, a rare, aggressive type of brain cancer called atypical teratoid rhabdoid tumors tend to ...
Loading Comments...